Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 11/20 | 0.74 |
| ▸ | MMP2 | P08253 | 9/20 | 0.74 |
| ▸ | MMP1 | P03956 | 9/20 | 0.74 |
| ▸ | MMP13 | P45452 | 8/20 | 0.74 |
| ▸ | MMP3 | P08254 | 6/20 | 0.74 |
| ▸ | MMP7 | P09237 | 6/20 | 0.74 |
| ▸ | MMP8 | P22894 | 1/20 | 0.69 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.66 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.59 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.59 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7376000 | 1.00 | MMP9 (0.74) | MMP9MMP2MMP1MMP13MMP3 | |
| SCHEMBL7417565 | 0.85 | MMP9 (0.64) | MMP9MMP2MMP1MMP13MMP3 | |
| SCHEMBL7347163 | 0.85 | MMP9 (0.72) | MMP9MMP2MMP1MMP13MMP3 | |
| SCHEMBL2161452 | 0.85 | MMP9 (0.92) | MMP9MMP2MMP1MMP13MMP3 | |
| SCHEMBL2161549 | 0.85 | MMP9 (0.92) | MMP9MMP2MMP1MMP13MMP3 | |
| SCHEMBL6723663 | 0.85 | MMP9 (0.72) | MMP9MMP2MMP1MMP13MMP3 | |
| SCHEMBL5839717 | 0.85 | MMP9 (0.92) | MMP9MMP2MMP1MMP13MMP3 | |
| SCHEMBL6723666 | 0.85 | MMP9 (0.72) | MMP9MMP2MMP1MMP13MMP3 | |
| SCHEMBL7419690 | 0.84 | MMP2 (0.91) | MMP9MMP2MMP1MMP13MMP3 | |
| SCHEMBL7420442 | 0.83 | MMP1 (0.69) | MMP9MMP2MMP1MMP13MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934267-B1 | ALPHA-AMINO SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | UPJOHN CO (US) | 2002-01-30 | — | — | EP | claimed |
| US-5804593-A | FOR TREATMENT OF CONNECTIVE TISSUE DEGRADATION, OSTEO-, RHEUMATOID-, AND SEPTIC ARTHRITIS; OSTEOPENIAS, OSTEOPOROSIS, CORNEAL ULCERATION, PERIDONTAL DISEASE, GASTRIC ULCERS. | PHARMACIA & UPJOHN COMPANY (US) | 1998-09-08 | — | — | US | claimed |
| EP-0934267-B1 | ALPHA-AMINO SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | UPJOHN CO (US) | 2002-01-30 | — | — | EP | disclosed |
| US-6218389-B1 | FOR THERAPY AND PROPHYLAXIS OF ARTHRITIS, CANCER, CARDIOVASCULAR DISORDERS; SKIN DISORDERS; OCULAR DISORDERS; INFLAMMATION AND GUM DISEASES, MULTIPLE SCLEROSIS, CACHEXIA, PREVENTING LOOSENING OF PROSTHETIC DEVICES | THE PROCTER & GAMBLE CO. | 2001-04-17 | — | — | US | disclosed |
| EP-1009737-A2 | SULFONYLAMINO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2000-06-21 | — | — | EP | disclosed |
| EP-0934267-A1 | $g(a)-AMINO SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1999006340-A2 | SULFONYLAMINO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 1999-02-11 | — | — | WO | disclosed |
| US-5804593-A | FOR TREATMENT OF CONNECTIVE TISSUE DEGRADATION, OSTEO-, RHEUMATOID-, AND SEPTIC ARTHRITIS; OSTEOPENIAS, OSTEOPOROSIS, CORNEAL ULCERATION, PERIDONTAL DISEASE, GASTRIC ULCERS. | PHARMACIA & UPJOHN COMPANY (US) | 1998-09-08 | — | — | US | disclosed |
| WO-1998017645-A1 | α-AMINO SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1998-04-30 | — | — | WO | disclosed |